MD960168A - Method for treatment of viral infections and compounds therefor - Google Patents

Method for treatment of viral infections and compounds therefor

Info

Publication number
MD960168A
MD960168A MD96-0168A MD960168A MD960168A MD 960168 A MD960168 A MD 960168A MD 960168 A MD960168 A MD 960168A MD 960168 A MD960168 A MD 960168A
Authority
MD
Moldova
Prior art keywords
viral infections
treatment
compounds therefor
compounds
therefor
Prior art date
Application number
MD96-0168A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Odur Ayuko Washington
Original Assignee
Radopath Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Limited filed Critical Radopath Limited
Publication of MD960168A publication Critical patent/MD960168A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the method and compounds for mammals viral infections treatment.In the composition there is used flavin and derivatives thereof.The technical result consists in increasing the effectiveness of viral infections treatment.
MD96-0168A 1993-10-19 1996-05-17 Method for treatment of viral infections and compounds therefor MD960168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
PCT/GB1994/002292 WO1995011028A1 (en) 1993-10-19 1994-10-19 Flavin derivatives as anti-viral agents

Publications (1)

Publication Number Publication Date
MD960168A true MD960168A (en) 1998-04-30

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0168A MD960168A (en) 1993-10-19 1996-05-17 Method for treatment of viral infections and compounds therefor

Country Status (26)

Country Link
EP (1) EP0739208A1 (en)
JP (1) JPH09505804A (en)
CN (1) CN1140992A (en)
AP (1) AP620A (en)
AU (1) AU7943794A (en)
BG (1) BG100599A (en)
BR (1) BR9407862A (en)
CA (2) CA2123825A1 (en)
CO (1) CO4520283A1 (en)
CZ (1) CZ113796A3 (en)
EE (1) EE9600057A (en)
GB (2) GB9321558D0 (en)
HR (1) HRP940688A2 (en)
HU (1) HUT76322A (en)
IL (1) IL111338A0 (en)
JO (1) JO1866B1 (en)
MA (1) MA23356A1 (en)
MD (1) MD960168A (en)
NO (1) NO961547L (en)
OA (1) OA10579A (en)
PE (1) PE5596A1 (en)
PL (1) PL314008A1 (en)
SK (1) SK50696A3 (en)
UY (1) UY23844A1 (en)
WO (1) WO1995011028A1 (en)
ZA (1) ZA948191B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (en) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd Interferon activity-enhancing agent and antivirus activity-enhancing composition containing the enhancing agent and interferon
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2003299486A1 (en) * 2002-05-10 2004-06-03 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (en) 2002-07-16 2004-01-16 Dayco Europe Srl INTEGRATED PULLEY-TORSIONAL DAMPER GROUP
CN100413866C (en) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 Riboflavin derivative and its preparation method and uses
EP2545788A1 (en) * 2011-07-13 2013-01-16 Martin Hulliger Dietary multi-component system
JP2018131410A (en) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 Caspase-3 inhibitor and use thereof
CN111565715A (en) * 2017-10-24 2020-08-21 卢内拉生物技术有限公司 Mitoflavoscin: elimination of Cancer Stem Cells (CSCS) by inhibition of mitochondrial respiration with enzymes containing targeted flavins
CN114126603A (en) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 Reduction of viral activity of elaverde with riboflavin or DHA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (en) * 1989-09-14 1998-03-11 三井農林株式会社 Influenza virus infection prevention agent
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (en) * 1991-04-02 1995-03-10 Jean Berque NEW THERAPEUTIC INDICATIONS, PARTICULARLY FOR THE TREATMENT OF AIDS, OF AN ALREADY EXISTING MEDICINAL PRODUCT FROM A DENIMOUS MOLECULE OF CONTRAINDICATIONS AND ADVERSE REACTIONS.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (en) * 1992-03-27 2000-08-07 雪印乳業株式会社 Sialic acid-bound 5-deazaflavin compounds

Also Published As

Publication number Publication date
GB9321558D0 (en) 1993-12-08
GB9421099D0 (en) 1994-12-07
CA2174552A1 (en) 1995-04-27
BR9407862A (en) 1997-05-20
OA10579A (en) 2002-06-19
HUT76322A (en) 1997-08-28
WO1995011028A1 (en) 1995-04-27
CO4520283A1 (en) 1997-10-15
PL314008A1 (en) 1996-08-05
CA2123825A1 (en) 1995-04-20
NO961547D0 (en) 1996-04-18
JO1866B1 (en) 1995-12-27
PE5596A1 (en) 1996-04-18
HRP940688A2 (en) 1997-04-30
AU7943794A (en) 1995-05-08
IL111338A0 (en) 1994-12-29
NO961547L (en) 1996-06-19
SK50696A3 (en) 1997-01-08
BG100599A (en) 1997-02-28
CZ113796A3 (en) 1996-11-13
MA23356A1 (en) 1995-07-01
ZA948191B (en) 1995-06-08
HU9601006D0 (en) 1996-06-28
JPH09505804A (en) 1997-06-10
EP0739208A1 (en) 1996-10-30
UY23844A1 (en) 1995-03-28
AP620A (en) 1997-10-14
GB2283913A (en) 1995-05-24
CN1140992A (en) 1997-01-22
EE9600057A (en) 1996-10-15
AP9400695A0 (en) 1995-01-31

Similar Documents

Publication Publication Date Title
GB8821049D0 (en) Method & composition for treatment & prevention of viral infections
MY101842A (en) Treatment of oral diseases.
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
MX9702932A (en) L-ribofuranosyl nucleosides.
AU2500097A (en) Compositions containing bacteriophages and methods of using bacteriophages to treat infections
ES2149276T3 (en) IMIDAZO (4,5-C) PIRIDIN-4-AMINAS.
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
MD1838G2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
UA41355C2 (en) Agent for treating neuro-aids
RU94020410A (en) Method of vomiting treatment or prophylaxis in mammalian and human using the certain quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds
DE69407272D1 (en) METHOD FOR PURIFYING 20 CS) -CAMPTOTHECIN
ES8800160A1 (en) 5,6-Difluoronaphthyridines and 5,6,8-trifluoro-quinolines as antibacterial agents.
MD960168A (en) Method for treatment of viral infections and compounds therefor
FI945000A0 (en) Process for the preparation of (S) -amino-1-substituted pyrrolidines
AU3206297A (en) Composition and method for treating herpes simplex
MX9702926A (en) L-erythrosyl nucleosides.
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
AU8192691A (en) Method of treatment and compositions therefore
FI961380A (en) Compositions for the prevention and treatment of viral tumors
AU6796287A (en) Method and composition for prophylaxis and treatment of viral infections
EP0594795A4 (en) Michellamines useful as antiviral agents, composition and method of treatment.
ZA87470B (en) Method and composition for prophylaxis and treatment of viral infections
ZA949564B (en) Method for treating constipation using dimeticone.
MX9702927A (en) L-pyranosyl nucleosides.
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections

Legal Events

Date Code Title Description
FA1A Withdrawn application

Free format text: 19990225